Ibulocydine is a novel prodrug cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells

Journal of Biological Chemistry

Volumn 286, Issue 22, 2011, Pages 19662-19671

  Cho, Seung Ju ^a,b   Kim, Young Jong ^b   Surh, Young Joon ^a   Kim, B Moon ^b   Lee, Seung Ki ^a,b  

^a Research Institute of Pharmaceutical Sciences   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICANCER DRUG; APOPTOSIS; CARBOXYL-TERMINAL DOMAIN; CDK INHIBITORS; CELL CYCLE REGULATION; CELL TYPES; CYCLIN-DEPENDENT KINASE; DOWN-REGULATION; GENE PRODUCTS; HEPATOCELLULAR CARCINOMA; HEPATOCELLULAR CARCINOMA CELL; HEPATOCYTES; HIGH ACTIVITY; IN-VITRO; INDUCED APOPTOSIS; OLOMOUCINE; PRODRUGS; RNA POLYMERASE II; ROSCOVITINE; SURVIVIN; TOXIC SIDE EFFECTS;

DISEASES; DRUG PRODUCTS; GENES; PHOSPHORYLATION; RNA;

CELL DEATH;

ANTINEOPLASTIC AGENT; BMK Y 101; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN H; CYCLIN T; IBULOCYDINE; OLOMOUCINE; PROTEIN MCL 1; RNA POLYMERASE II; ROSCOVITINE; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOMA CELL; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; DRUG ELIMINATION; DRUG URINE LEVEL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; DRUG SCREENING ASSAYS, ANTITUMOR; HEP G2 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MICE; PRODRUGS; PROTEIN KINASE INHIBITORS; PYRIMIDINE NUCLEOSIDES; RNA POLYMERASE II;

EID: 79957604201     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M110.209551     Document Type: Article

References (39)

1. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2005)CACancer J. Clin. 55, 74-108
2. Bolondi, L., Sofia, S., Siringo, S., Gaiani, S., Casali, A., Zironi, G., Piscaglia, F., Gramantieri, L., Zanetti, M., and Sherman, M. (2001) Gut 48, 251-259
3. El-Serag, H. B., and Rudolph, K. L. (2007) Gastroenterology 132, 2557-2576
4. El-Serag, H. B., Davila, J. A., Petersen, N. J., and McGlynn, K. A. (2003) Ann. Intern. Med. 139, 817-823
5. Mendizabal, M., and Reddy, K. R. (2009) Med. Clin. N. Am. 93, 885-900, viii
6. Huang, C. C., Wu, M. C., Xu, G. W., Li, D. Z., Cheng, H., Tu, Z. X., Jiang, H. Q., and Gu, J. R. (1992) J. Natl. Cancer Inst. 84, 262-264
7. Senderowicz, A. M. (2003) Oncogene 22, 6609-6620
8. Swanton, C. (2004) Lancet Oncol. 5, 27-36
9. Senderowicz, A. M. (2004) Curr. Opin. Cell. Biol. 16, 670-678
10. Ito, Y., Takeda, T., Sakon, M., Monden, M., Tsujimoto, M., and Matsuura, N. (2000) Oncology 59, 68-74
11. Malumbres, M., Pevarello, P., Barbacid, M., and Bischoff, J. R. (2008) Trends Pharmacol. Sci. 29, 16-21
12. Nurse, P. (2000) Cell 100, 71-78
13. Nurse, P. M. (2002) Biosci. Rep. 22, 487-499
14. Kimura, K., Hirano, M., Kobayashi, R., and Hirano, T. (1998) Science 282, 487-490
15. Bregman, D. B., Pestell, R. G., and Kidd, V. J. (2000) Front. Biosci. 5, D244-257
16. Yankulov, K. Y., and Bentley, D. L. (1997) EMBO J. 16, 1638-1646
17. Chao, S. H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., and Price, D. H. (2000) J. Biol. Chem. 275, 28345-28348
18. Peterlin, B. M., and Price, D. H. (2006) Mol. Cell. 23, 297-305
19. Oelgeschläger, T. (2002) J. Cell. Physiol. 190, 160-169
20. MacCallum, D. E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella- Borradori, A., Lane, D. P., and Green, S. R. (2005) Cancer Res. 65, 5399-5407
21. Cho, S. J., Lee, S. S., Kim, Y. J., Park, B. D., Choi, J. S., Liu, L., Ham, Y. M., Kim, B., and Lee, S. K. (2010) Cancer Lett. 287, 196-206
22. Coultas, L., and Strasser, A. (2003) Semin. Cancer Biol. 13, 115-123
23. Yang, T., Buchan, H. L., Townsend, K. J., and Craig, R. W. (1996) J. Cell. Physiol. 166, 523-536
24. Zhang, B., Gojo, I., and Fenton, R. G. (2002) Blood 99, 1885-1893
25. Derenne, S., Monia, B., Dean, N. M., Taylor, J. K., Rapp, M. J., Harousseau, J. L., Bataille, R., and Amiot, M. (2002) Blood 100, 194-199
26. Gojo, I., Zhang, B., and Fenton, R. G. (2002) Clin. Cancer Res. 8, 3527-3538
27. Michels, J., O'Neill, J. W., Dallman, C. L., Mouzakiti, A., Habens, F., Brimmell, M., Zhang, K. Y., Craig, R. W., Marcusson, E. G., Johnson, P. W., and Packham, G. (2004) Oncogene 23, 4818-4827
28. Gomez-Bougie, P., Bataille, R., and Amiot, M. (2004) Eur. J. Immunol. 34, 3156-3164
29. Salvesen, G. S., and Duckett, C. S. (2002) Nat. Rev. Mol. Cell Biol. 3, 401-410
30. Silverman, R. B. (2004) The Organic Chemistry of Drug Design and Drug Action, 2nd Ed., pp. 497-558, Elsevier Academic Press, New York
31. Wu, K. M. (2009) Pharmaceuticals 2, 77-81
32. Sinhababu, A. K., and Thakker, D. R. (1996) Adv. Drug. Del. Rev. 19, 241-273
33. Svendsen, A. (2000) Biochim. Biophys. Acta 1543, 223-238
34. Hirose, Y., and Manley, J. L. (2000) Genes Dev. 14, 1415-1429
35. Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., Wahl, L. M., Harris, E. D., Mikovits, J. A., Monks, A. P., Hollingshead, M. G., Sausville, E. A., and Staudt, L. M. (2001) Genome Biol. 2, RESEARCH0041
36. Chen, R., Wierda, W. G., Chubb, S., Hawtin, R. E., Fox, J. A., Keating, M. J., Gandhi, V., and Plunkett, W. (2009) Blood 113, 4637-4645
37. Hahntow, I. N., Schneller, F., Oelsner, M., Weick, K., Ringshausen, I., Fend, F., Peschel, C., and Decker, T. (2004) Leukemia 18, 747-755
38. Knudsen, E. S., and Wang, J. Y. (1996) J. Biol. Chem. 271, 8313-8320
39. Zarkowska, T., and Mittnacht, S. (1997) J. Biol. Chem. 272, 12738-12746